SAREPTA THERAPEUTICS, INC. Gain (Loss) on Extinguishment of Debt
SAREPTA THERAPEUTICS, INC. (SRPT) reported Gain (Loss) on Extinguishment of Debt of $16.86 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was -$121.74M.
- SAREPTA THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was $138.60M.
- SAREPTA THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2024-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2024-09-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2025 was $16.86M.
- SAREPTA THERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- SAREPTA THERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2023 was -$387.33M.
- SAREPTA THERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2022 was -$125.44M.
| Period end | Gain (Loss) on Extinguishment of Debt 1 month | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 3 month as first filed | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 9 month as first filed | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$121.74M derived: 10-K 12 month − 10-K 9 month · filed 2026-03-02 | $16.86M derived: sum of 2 quarters · filed 2026-03-02 | $16.86M 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | $138.60M 10-K · filed 2026-03-02 | -$138.61M 10-Q · filed 2025-11-06 | $138.60M 10-K · filed 2026-03-02 | -$138.61M 10-Q · filed 2025-11-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | -$387.33M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | -$387.33M 10-Q · filed 2024-11-06 | -$387.33M derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | -$387.33M 10-Q · filed 2024-08-07 | -$387.33M derived: sum of 3 quarters · filed 2025-02-28 | -$512.77M derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2023-03-31 | -$387.33M 10-Q · filed 2024-05-01 | -$387.33M derived: sum of 2 quarters · filed 2025-02-28 | -$512.77M derived: sum of 3 quarters · filed 2025-02-28 | -$512.77M derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$125.44M derived: sum of 2 quarters · filed 2025-02-28 | -$125.44M derived: sum of 3 quarters · filed 2025-02-28 | -$125.44M 10-K · filed 2025-02-28 | |||
| 2022-09-30 | -$125.44M 10-Q · filed 2023-11-01 | -$125.44M derived: sum of 2 quarters · filed 2023-11-01 | -$125.44M 10-Q · filed 2023-11-01 | -$125.44M derived: sum of 4 quarters · filed 2024-02-28 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | $0.00 derived: sum of 4 quarters · filed 2024-02-28 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-02 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-02 | $0.00 10-Q · filed 2022-11-02 | |||||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 | ||||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$2.32M 10-K · filed 2021-03-01 | |||||
| 2018-09-30 | -$2.30M 10-K · filed 2020-02-26 | -$2.32M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |